Why I Am Buying This Specialty Drug Stock
There is a relief bounce on an in-line CPI report, but the inflation issue isn’t going away.
You've reached your free article limit
You've read 0 of 1 free Pro articles.
The market is enjoying a relief bounce on Wednesday after the May CPI report came in mixed enough to give the bulls a little relief. Headline CPI hit 4.2% year over year as expected, a fresh three-year high driven mainly by the Iran energy shock, but the core monthly reading came in cool at 0.2% versus the 0.3% consensus. That kept the worst-case scenario off the table and let the equity market work back into positive territory.
The CPI reaction is the kind of tentative bounce the market keeps producing lately. We did not get a hot report, but we did not get a meaningfully cool one either, and the longer Iran keeps oil elevated the more the inflation problem becomes structural rather than cyclical. The Fed meets June 16-17 with this number in front of them and the recent strong jobs report in mind, so the hawkish tilt is the base case.
Why I Added Harrow Today
Harrow Health (HROW) has been a disappointment since I first discussed it but I bought shares Wednesday. Despite some management stumbles, the long-term story is intact and a few catalysts are lining up.
Harrow is a specialty pharmaceutical company focused on the prescription ophthalmic market. The business model is to acquire or develop FDA-approved eye-care drugs that large pharma has deprioritized, then build a focused commercial organization around them.
The company’s portfolio includes IHEEZO for cataract surgery anesthesia, VEVYE for dry eye disease, and now the relaunched VERKAZIA for vernal keratoconjunctivitis. The 74% gross margin reflects the benefit of focusing on branded prescription products in a single specialty channel with limited generic competition.
Harrow’s Q1 earnings miss was the cause of the recent decline. Revenue came in at $44.2 million versus a $52.55 million estimate, the sort of headline number that gets a small-cap biotech sold without much further investigation. The shortfall was tied to an $8 million non-recurring gross-to-net adjustment from the VEVYE rollout, which is an accounting issue rather than a demand issue. Management reaffirmed full-year 2026 revenue guidance of $350 million to $365 million, which signals they expect a sharp Q2 recovery.
The insider buying after the selloff is the vote of confidence I want to see. CEO Mark Baum bought 10,000 shares at $30.20 on May 14 for $302,000. CFO Andrew Boll bought 3,500 shares at $29.90 the same day. Two board directors picked up 1,000 shares each on the open market. Cluster insider buying after a headline miss is a clear signal that management views the decline as a market overreaction rather than a fundamental shift in the company’s fortunes.
Harrow announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion 0.1%) Wednesday morning. VERKAZIA treats vernal keratoconjunctivitis, a chronic allergic eye disease that primarily affects children, and it is the only FDA-approved steroid-sparing therapy for that indication. It slots into Harrow’s existing commercial infrastructure and contributes to the high-margin portfolio.
Cantor Fitzgerald has an Overweight rating with an $88 price target. The stock is well below that level after the recent selloff, leaving plenty of room for a recovery if the Q2 report delivers what management has signaled.
The major risk is that Q2 earnings don’t show the recovery management has committed to. If revenue falls below the $71 million to $81 million range required to meet full-year guidance, the next selloff will be worse than the one we just had. That is why I am moving incrementally and will trade a portion of the position shorter term.
Strategy
Although we have a little bounce action, my defensive posture remains in place. CPI was constructive but confirms that inflation is heading in the wrong direction. Iran is unresolved, PPI tomorrow can move the picture either direction, and the SpaceX IPO Friday is a liquidity event that will move tech regardless of how it prices. The bounce Wednesday does not change the potential danger that is lurking.
What it does is create opportunities in names that are being sold for reasons unrelated to their actual business. Harrow is the example I am acting on today. The focus is on the stock and the business, not the macro-economic headlines.
At the time of publication, Rev Shark was long HROW.
